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 3 
Introduction 
 
Cardiovascular regenerative medicine (CRM) has been defined as an innovative research 
field that includes all diagnostic and therapeutic strategies aimed at restoring 
cardiovascular health by enhancing the innate regenerative response of cardiac and 
vascular tissues1. The Transnational Alliance for Regenerative Therapies in 
Cardiovascular Syndromes (TACTICS) was created in 2015 with the vision of advancing 
CRM through synergy of basic discoveries and translational clinical efforts in the fight 
against cardiovascular failure, and has grown to include more than 100 research groups 
worldwide2. This unprecedented initiative stated as specific missions the redefinition of 
CRM and advanced therapy regenerative products, the establishment of discovery and 
development priorities for the next decade and the attainment and dissemination of a 
consensual strategy to reinforce the field increasing its credibility. 
 
The first milestone of TACTICS has been achieved with the publication of a Global 
Consensus Document1. However, given the amplitude and relevance of its different 
chapters, a more detailed description of all of them has been deemed necessary, following 
the same scheme of the Global Consensus Document and therefore discussing the main 
topics and priorities of the CRM field. 
 
This is the final aim of this “Cardiovascular Regenerative and Reparative Medicine” 
Circulation Research Review Series. In this first chapter, the following ones are presented 
and summarized in the form of and index of consecutive manuscripts, which will cover 
biological fundamentals, preclinical models and all clinical research-related issues. These 
manuscripts will be regularly and subsequently published in this journal, on behalf of the 
TACTICS Consortium (Figure 1). 
 
Chapter 2. Translational Research in Cardiovascular Repair: a Call for a Paradigm 
Shift 
 
The hypothesis of CRM being able to revolutionize cardiovascular clinical practice has 
been based on the mainly positive and overall consistent results of preclinical research. 
However, the lack of homogenous definitions in preclinical models and of blinded and 
multicentre studies have hampered eventual comparisons between them, and could 
explain the discrepancies observed between the results of preclinical studies and human 
clinical trials. Despite the inherent limitations of preclinical studies (which exist not only 
in CRM, but in all areas of biomedical research), the need for infrastructures, protocols 
and technologies that would allow the translation of CRM products to clinical practice is 
increasingly recognised. In this chapter, specific recommendations will be made to 
overcome the aforementioned limitations of translational research. Specifically, solutions 
to guide researchers and regulatory bodies to conduct more efficient preclinical studies 
will be presented.  
 
Chapter 3. Cardiovascular Regenerative Products and Mechanisms of Cardiac 
Regeneration 
 
The paradigm that cardiomyocytes are terminally differentiated cells with no capacity for 
proliferation or renewal has been abandoned, and the heart is now recognized to be a self-
renewing organ. However, the mechanisms involved in this natural process of renewal in 
the cardiovascular system remain under debate. From lower vertebrates to mammals, 
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 4 
cardiac regenerative capacities extensively differ but probably share similar pathways and 
mechanisms. The main effectors of the process of regeneration and their interactions will 
be described in this chapter (ie, cardiac aging, cell-to-cell communications, differentiation 
and dedifferentiation, inflammatory responses, proliferation processes, etc). Furthermore, 
latest achievements in the development of effective therapeutic approaches to modulate 
these regenerative and reparative processes will be presented.  
 
Chapter 4. IMPACT: Preclinical Studies of Cell Therapy for Human Diseases 
 
Focusing on cell therapies, chapter 4 will critically discuss promising preclinical studies 
using a variety of stem cells with innovative approaches in different models of cardiac 
disease. The beneficial effects of certain types of stem cells when delivered in a single 
dose or the use of just one cell source may be negligible. Conversely, the development of 
novel strategies such as the combination of different types of stem cells, the repetitive 
administration of cells or the implementation of techniques designed to improve 
engraftment and retention rates are being increasingly investigated. These innovative 
preclinical approaches have showed better results and will pave the way for future – and 
hopefully positive – clinical trials. Finally, preclinical research needs to be designed 
simultaneously with future clinical trials in order to ensure a cost-effective and time-
efficient development. 
 
Chapter 5. Priorities in Fundamental Regenerative Knowledge and Innovative 
Research: from Genes to Tissue Engineering 
 
Basic research is the cornerstone of clinical advances. This chapter will summarize and 
discuss those areas of research where more extensive knowledge is needed in order to 
develop more effective regenerative treatments. The identification of biological processes 
involved in embryonic development and in innate mechanisms of regeneration are 
mandatory in order to identify therapeutic targets and novel strategies for the 
enhancement of endogenous regenerative responses. In addition, disruptive therapies 
such as cell-free modalities, safe and controlled gene-editing technologies, tissue 
engineering approaches or even the creation of chimeric organs are under evaluation and 
will be critically discussed.  
 
Chapter 6. Identification of Regenerative Products Ready for Clinical Research 
 
This chapter will be focused on advanced therapy medicinal products for cardiac and 
vascular repair. First, second and third-generation stem cells, episomes and gene 
therapies, cell-free solutions (ie, mRNA, microvesicles, exosomes and growth factors), 
biomaterials and tissue engineering products will be presented and analysed in terms of 
readiness and convenience for full clinical assessment. Taking into account that all these 
products and all clinical research tracks must be grounded on evidence-based translational 
rationales and have to undergo the traditional four phases of clinical research, a critical 
reflection will be offered with a special focus on unsettled issues with implications on 
outcomes. In some cases, these uncertainties should be further explored before moving 
into new clinical trials. They include best tolerated doses, benefits of repetitive 
administration, optimal timing, comparative experiments with different products, 
combinatorial approaches and most efficient delivery modalities for each product and 
condition. Final considerations will be also offered on product standardization and on 
mechanistic trials that will increase our knowledge on mechanisms of action.  
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Chapter 7. Priorities of Clinical Cardiovascular Regenerative Research. Design of 
Clinical Trials. Methods for Delivery, Tracking and Assessment  
 
One of the most controversial debates in the CRM field is the design of future clinical 
trials. Indeed, the main obstacles that clinical CRM has encountered since its inception 
and that have hampered its large-scale adoption in daily clinical practice include 
heterogeneity of study protocols and underestimation of aspects such as patient selection, 
delivery methods and imaging-based assessment of the outcomes. Furthermore, surrogate 
and clinical endpoints have been inconsistently used and are usually misinterpreted. In 
this chapter, objectives, selection criteria, safety and efficacy endpoints (hard, surrogate 
and composite), sample size calculation, design modalities and clinical research phases 
will be discussed in the light of available evidence.  
 
As part of trial design, the use of biomarkers, new imaging and tracking modalities and 
reflections on delivery techniques will be included. Special emphasis will be laid on the 
development of minimally invasive methodologies for tissue engineering solutions and 
on the optimization of delivery modalities to improve accuracy by means of fusion 
imaging tools. Finally, new automated software to guide and improve product delivery 
and retention (ie, real-time integration of computed tomography, magnetic resonance and 
ultrasound into the catheter navigation process) and novel imaging technologies for in 
vivo tracking of regenerative products in humans will be presented.   
 
Chapter 8. From the Lab to the Market: Recommendations Regarding Regulatory, 
Funding Strategies and Final Interaction with Public Opinion 
 
The goal of this chapter will be to provide recommendations regarding important aspects 
which may accelerate the translation of advanced therapy regenerative products into the 
clinics. The standardization of biological therapies presents specific characteristics that 
cannot be evaluated following the procedures developed for the pharmaceutical industry. 
The essential role of competent authorities to identify international mechanisms for the 
oversight of regenerative treatments (avoiding unregulated scenarios) and the need for 
customized regulatory pathways that would facilitate CRM research, will be discussed. 
Linked with this, funding strategies may be enhanced by cooperative networks (ie, 
TACTICS), underscoring the importance of true international collaboration to move the 
field definitely forward. Last but not least, the interaction with public opinion, media, 
decision makers and the rest of the scientific community is of utmost importance, given 
the negative climate that has been created around the whole field during the last years and 
that should be revisited. 
 
Chapter 9. Role of Immunology and Inflammation on Cardiovascular Regenerative 
Medicine 
 
The biological basis of all types of damage to the cardiovascular system involve cellular 
effectors and molecular signals that regulate the inflammatory and reparative responses 
after those insults. The field of CRM is closely related to these mechanisms, which are 
not yet completely understood and which may be modulated to improve the efficacy of 
regenerative products in patients with acute myocardial infarction, stroke, peripheral 
artery disease and heart failure. Furthermore, the increasing use of allogeneic products 
because of their distinctive immunological behavior with immunomodulatory beneficial 
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 6 
effects, their strictly quality-controlled manufacturing and their readily availability, 
warrant further investigations. Both topics (ie, inflammation and immunology) will be 
discussed in this chapter. 
 
Summary 
 
The main objective of this series of articles is to describe and reflect on the priorities of 
cardiovascular regenerative research from a critical point of view, promoting an open 
discussion about the lights and shadows of the field, increasing its credibility and 
facilitating the advance of CRM to definitely repair the failing cardiovascular system. 
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FIGURE LEGEND 
 
Figure 1. Schematic representation of all manuscripts included in this Review Series. 
TACTICS: Transnational Alliance for Regenerative Therapies in Cardiovascular 
Syndromes. 
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